Sumitomo Pharma America, Inc. (SMPA) today announced the launch of Time to Go: Pit Stops with the Peetes, the latest chapter of its Time To Go campaign featuring Holly Robinson Peete and Rodney Peete. The new campaign follows the GEMTESA Go-Getters, or brand ambassadors, on a series of road trip “pit stops,” where they share their experiences living with overactive bladder (OAB) and how treatment with GEMTESA® (vibegron) has helped them manage their symptoms.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102014696/en/
“Sumitomo Pharma America, Inc. is proud to continue our partnership with Holly Robinson Peete and Rodney Peete to raise awareness about overactive bladder and its symptoms in both men and women,” said Alana Darden Powell, Vice President of Biopharma Marketing for SMPA. “With Time To Go: Pit Stops with the Peetes, we’re helping spotlight how OAB can interrupt everyday moments, from road trips to time with loved ones, and encouraging men and women to have conversations with their doctor about treatment options. Our hope is to reduce stigma surrounding bladder health and empower patients with the information they need to spend less time planning around their symptoms and more time enjoying the moments that matter.”
Time To Go is a campaign designed to raise awareness of overactive bladder, encourage conversations with healthcare providers, and help people learn about their treatment options. In its newest chapter, Time To Go: Pit Stops with the Peetes, Holly and Rodney share how a favorite activity of theirs—road tripping—used to frequently be interrupted by OAB, and how treatment with GEMTESA has helped them spend less time planning around bathroom breaks and more time enjoying the journey.
GEMTESA is a prescription medicine for the treatment of OAB in adults, and in adult males taking medicine for benign prostatic hyperplasia (BPH), with symptoms of urge urinary incontinence, urgency, and frequency. Overactive bladder (OAB) causes sudden urges to urinate that are difficult to control and can result in leakage, as well as frequent urination — usually eight or more times a day2. Overactive bladder can disrupt everyday life with nearly 2 in 10 men and women in the U.S. experiencing symptoms1, which can be bothersome and have a meaningful impact on daily life.
“I’m excited to continue the partnership with GEMTESA and Sumitomo Pharma and to continue to raise awareness about this condition that impacts so many people,” said Holly Robinson Peete, actor and activist. “Traveling has always been one of my passions, and I used to worry about getting stuck in a crowded airport, plane, or being miles away from the nearest bathroom. Since starting GEMTESA, my symptoms have reduced significantly, and I don’t have to worry as much about going to the bathroom as often as I used to.”
“Holly and I love taking road trips together but, in the past, because of my OAB, we often had to make unplanned stops – I even started carrying a ‘Travel John,’” said Rodney. “Now with symptom relief thanks to GEMTESA, I don’t have to worry about stopping so often to go to the bathroom and can be more in the moment with Holly.”
People experiencing OAB symptoms are encouraged to talk to their doctor to get a diagnosis and determine the best treatment option(s) to help them manage the condition. To learn more about OAB and GEMTESA, or hear from other GEMTESA Go-Getters, visit TimeToGo.com.
About Overactive Bladder
Overactive bladder (OAB) is a clinical condition that occurs when the bladder muscle contracts involuntarily. Symptoms may include urinary urgency (the sudden urge to urinate that is difficult to control), urgency incontinence (unintentional loss of urine immediately after an urgent need to urinate), and frequent urination (usually eight or more times in 24 hours).2 About 33 million U.S. adults experience the bothersome symptoms of OAB.3
About GEMTESA
GEMTESA® (vibegron) is a prescription medicine for adults used to treat the following symptoms due to a condition called overactive bladder in adults, and in adult males taking medicine for benign prostatic hyperplasia (BPH):
- urge urinary incontinence: a strong need to urinate with leaking or wetting accidents
- urgency: the need to urinate right away
- frequency: urinating often
It is not known if GEMTESA is safe and effective in children.
IMPORTANT SAFETY INFORMATION
Do not take GEMTESA if you are allergic to vibegron or any of the ingredients in GEMTESA.
Before you take GEMTESA, tell your doctor about all your medical conditions, including if you have liver problems; have kidney problems; have trouble emptying your bladder or you have a weak urine stream; take medicines that contain digoxin; are pregnant or plan to become pregnant (it is not known if GEMTESA will harm your unborn baby; talk to your doctor if you are pregnant or plan to become pregnant); are breastfeeding or plan to breastfeed (it is not known if GEMTESA passes into your breast milk; talk to your doctor about the best way to feed your baby if you take GEMTESA).
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.
What are the possible side effects of GEMTESA?
GEMTESA may cause serious side effects including:
- inability to empty your bladder (urinary retention). GEMTESA may increase your chances of not being able to empty your bladder, especially if you have bladder outlet obstruction or take other medicines for treatment of overactive bladder. Tell your doctor right away if you are unable to empty your bladder.
- angioedema. GEMTESA may cause an allergic reaction with swelling of the lips, face, tongue, or throat, with or without difficulty breathing. Stop using GEMTESA and tell your doctor right away.
The most common side effects of GEMTESA include headache, urinary tract infection, nasal congestion, sore throat or runny nose, diarrhea, nausea and upper respiratory tract infection. These are not all the possible side effects of GEMTESA. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Please see accompanying full Product Information.
About Sumitomo Pharma
Sumitomo Pharma Co., Ltd. is a global pharmaceutical company based in Japan with key operations in the U.S. (Sumitomo Pharma America, Inc.), Canada (Sumitomo Pharma Canada, Inc.) and Europe (Sumitomo Pharma Switzerland GmbH) focused on developing and delivering innovative pharmaceutical and regenerative medicines to meet patient needs across oncology, urology, women’s health, rare diseases, and CNS. With several marketed products in the U.S., Canada, and Europe, and a diverse pipeline of early- to late-stage assets, we aim to accelerate discovery, research, and development to bring novel therapies to patients sooner. For more information on SMPA, visit our website https://www.us.sumitomo-pharma.com/ or follow us on LinkedIn.
The Sumitomo corporate symbol mark is a registered trademark of Sumitomo Pharma Co., Ltd., used under license. SUMITOMO PHARMA is a trademark of Sumitomo Pharma Co., Ltd., used under license.
SUMITOMO is a registered trademark of Sumitomo Chemical Co., Ltd., used under license. Sumitomo Pharma America, Inc. is a U.S. subsidiary of Sumitomo Pharma Co., Ltd.
GEMTESA and its logo are registered trademarks of Sumitomo Pharma Co., Ltd., used under license.
©2026 Sumitomo Pharma America, Inc. All rights reserved. GEM-US-0447-26 11/26
References:
- Stewart, W. F., Van Rooyen, J. B., Cundiff, G. W., Abrams, P., Herzog, A. R., Corey, R., Hunt, T. L., & Wein, A. J. (2003). Prevalence and burden of overactive bladder in the United States. World Journal of Urology, 20(6), 327–336. https://doi.org/10.1007/s00345-002-0301-4
- Mayo Clinic. (2025, February 4). Overactive bladder – Symptoms and causes. Mayo Clinic.
- Gomelsky, A., & Dmochowski, R. R. (2010). Update on the management of overactive bladder: Patient considerations and adherence. Open Access Journal of Urology, 3, 7–17. https://pmc.ncbi.nlm.nih.gov/articles/PMC3818931/
View source version on businesswire.com: https://www.businesswire.com/news/home/20261102014696/en/
Media gallery
